'Plasma exchange reverses aging' is a commercial claim the human data doesn't support
Longevity clinics and influencers (Bryan Johnson's Blueprint among them) market plasma exchange/apheresis as "age reversal." But a 2025 randomized human trial of plasmapheresis (Borsky et al., Sci Rep, 1 Jul 2025; DOI 10.1038/s41598-025-05396-0, PMID 40592961) — co-authored by epigenetic-clock and longevity-industry figures — found NO epigenetic rejuvenation and signs of accelerated clocks (GrimAge, Hannum, DunedinPACE). The lab object and the sales claim are different things.
Total plasma exchange (TPE) and plasmapheresis — filtering "pro-aging factors" out of blood — have become a flagship offering of longevity clinics and a staple of the biohacker discourse (Bryan Johnson publicly ran, and abandoned, a family plasma-swap experiment with no measurable benefit). The commercial claim is "reverse your biological age." The peer-reviewed human evidence does not support that claim at the strength it is sold.
The cleanest test is a randomized cross-over human trial (Borsky et al., Scientific Reports, 1 Jul 2025; DOI 10.1038/s41598-025-05396-0, PMID 40592961) in healthy donors given 4 or 8 plasmaphereses over 18 weeks. It lowered cholesterol, non-HDL and triglycerides — but on epigenetic clocks it found no rejuvenation, and instead increases in DNAmGrimAge, the Hannum clock and the DunedinPACE pace-of-aging, concluding the protocol "may accelerate epigenetic aging" and needs more long-term safety study. A separate, small, single-blind Buck Institute TPE-plus-IVIG trial (reported 2025) claimed a modest ~2.6-year biological-age reduction on surrogate markers — unreplicated, short-term, surrogate-only, and not a hard clinical outcome.
Why it matters (money + metacrisis lever): plasma-exchange "longevity" packages sell for thousands of dollars per cycle. If the intervention doesn't work — or worsens aging clocks — it diverts money and hope from measures with real evidence, and it discredits the aging field (a reputational metacrisis lever in its own right). RDKG's value is drawing the verified-vs-hyped line before the consumer does.
Conflict-of-interest note: the rebuttal trial is itself entangled with the industry — authors include an epigenetic-clock foundation and Altos Labs figure (Steve Horvath) and a commercial "HealthyLongevity.Clinic." That a study with pro-longevity-industry authorship still found no benefit strengthens the skeptical read. The commercial sellers (clinics, influencer brands) profit directly from the age-reversal claim and are weighted separately from the paper.
What would prove it wrong (i.e., de-hype it): a large, blinded, randomized trial of a defined plasma-exchange protocol shows durable improvement in a hard clinical outcome (function, morbidity, mortality) — not just a surrogate clock — with independent replication. Absent that, "age reversal" is a marketing claim.
Live-status check (as of 2026-07-07): no plasma-exchange protocol is an FDA-approved anti-aging therapy; use for that indication is off-label/consumer. Human evidence is limited, mixed and surrogate-only; the best-controlled trial (2025) found possible clock acceleration. Commercial search interest and clinic marketing surged through mid-2026.
Informational only — not medical advice. Cite the primary trial (DOI above) and label the ~2.6-year figure as an unreplicated secondary claim; do not reproduce.
Tier the commercial "plasma exchange = age reversal" claim as HYPE and keep the underlying lab science as a separate, weak surrogate signal. Use this as a canonical house-rule example: peer-reviewed data and founder-branded commercial claims are DIFFERENT OBJECTS — even when clock scientists sit on both sides.
domains: plasma-exchange · apheresis · biological-age · longevity · commercial-claim · hype